These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21984220)

  • 41. High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform.
    Lee DW; Choi YS; Seo YJ; Lee MY; Jeon SY; Ku B; Kim S; Yi SH; Nam DH
    Anal Chem; 2014 Jan; 86(1):535-42. PubMed ID: 24199994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic index: a vital component in selection of anticancer agents for clinical trial.
    Double JA; Bibby MC
    J Natl Cancer Inst; 1989 Jul; 81(13):988-94. PubMed ID: 2659805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro.
    Aleskog A; Bashir-Hassan S; Hovstadius P; Kristensen J; Höglund M; Tholander B; Binderup L; Larsson R; Jonsson E
    Anticancer Drugs; 2001 Nov; 12(10):821-7. PubMed ID: 11707649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development.
    Unger C; Kramer N; Walzl A; Scherzer M; Hengstschläger M; Dolznig H
    Adv Drug Deliv Rev; 2014 Dec; 79-80():50-67. PubMed ID: 25453261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A rapid in vitro screening system for the identification and evaluation of anticancer drugs.
    Kao JW; Collins JL
    Cancer Invest; 1989; 7(4):303-11. PubMed ID: 2590857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. System models, assays and endpoint parameters to evaluate anticancer compounds during preclinical screening.
    Yakisich JS
    Curr Med Chem; 2014; 21(35):3985-98. PubMed ID: 23701499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.
    Li X; Qian L; Hua J; Bittner ML; Dougherty ER
    BMC Genomics; 2012; 13 Suppl 6(Suppl 6):S11. PubMed ID: 23134733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design.
    Eskens FA; Verweij J
    Crit Rev Oncol Hematol; 2000 May; 34(2):83-8. PubMed ID: 10799834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Points to consider on the non-clinical safety evaluation of anticancer drugs.
    Nakae D; Onodera H; Fueki O; Urano T; Komiyama N; Sagami F; Kai S; Nishimura C; Inoue T
    J Toxicol Sci; 2008 May; 33(2):123-6. PubMed ID: 18544904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing Specificity of Anticancer Drugs In Vitro.
    Kluwe L
    J Vis Exp; 2016 Mar; (109):e53752. PubMed ID: 27078035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective anticancer activity of β-lactams derived from polyaromatic compound.
    Banik BK; Becker FF
    Mol Med Rep; 2010; 3(2):315-6. PubMed ID: 21472239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kidneys on Chips: Emerging Technology for Preclinical Drug Development.
    Yeung CK; Himmelfarb J
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):144-146. PubMed ID: 30274990
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of therapeutic agents on cellular respiration as an indication of metabolic activity.
    Ishikawa T; Zhu BL; Maeda H
    Hum Exp Toxicol; 2006 Mar; 25(3):135-40. PubMed ID: 16634332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statistical determination of synergy based on Bliss definition of drugs independence.
    Demidenko E; Miller TW
    PLoS One; 2019; 14(11):e0224137. PubMed ID: 31765385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary studies on the validity of in vitro measurement of drug toxicity using HeLa cells. IV. Therapeutic effects and side effects of 50 drugs related to the HeLa toxicity of the therapeutic concentrations.
    Ekwall B
    Toxicol Lett; 1981 Feb; 7(4-5):359-66. PubMed ID: 7222113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro three-dimensional tumor microenvironment models for anticancer drug discovery.
    Smalley KS; Lioni M; Noma K; Haass NK; Herlyn M
    Expert Opin Drug Discov; 2008 Jan; 3(1):1-10. PubMed ID: 23480136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug resistance : the clinical perspective.
    Anthoney DA; Kaye SB
    Methods Mol Med; 1999; 28():1-15. PubMed ID: 21374022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.
    Jiang W; Mautner VF; Friedrich RE; Kluwe L
    J Clin Neurol; 2015 Apr; 11(2):172-7. PubMed ID: 25851896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical drug development in 2012.
    Muggia F
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):xi-xii. PubMed ID: 22520986
    [No Abstract]   [Full Text] [Related]  

  • 60. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
    Shen M; Asawa R; Zhang YQ; Cunningham E; Sun H; Tropsha A; Janzen WP; Muratov EN; Capuzzi SJ; Farag S; Jadhav A; Blatt J; Simeonov A; Martinez NJ
    Oncotarget; 2018 Jan; 9(4):4758-4772. PubMed ID: 29435139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.